Clinical trial

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

NCT05859217

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Cabozantinib Normalized identity: cabozantinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Atezolizumab Normalized identity: atezolizumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-12-01

PhasePHASE2

Conditions

Lung Cancerverified · MONDO: lung cancer

NSCLC Stage IVunresolved

Metastatic NSCLC - Non-Small Cell Lung Cancerunresolved

Advanced NSCLCunresolved

Interventions

CabozantinibDRUG · verified · RxNorm: cabozantinib

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Sponsors & collaborators

Jun Zhang, MD, PhDlead sponsor

Exelixiscollaborator

Genentech, Inc.collaborator

Mapped research locations

Kansas CityMissouri, United States1 Kansas CityKansas, United States1 Overland ParkKansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05859217 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.